Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €34.10 EUR
Change Today -2.95 / -7.96%
Volume 703.9K
GLPG On Other Exchanges
Symbol
Exchange
EN Amsterdam
OTC US
OTC US
Frankfurt
As of 11:35 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

galapagos nv (GLPG) Snapshot

Open
€37.50
Previous Close
€37.05
Day High
€38.00
Day Low
€32.25
52 Week High
04/28/15 - €40.43
52 Week Low
10/16/14 - €10.00
Market Cap
1.1B
Average Volume 10 Days
431.1K
EPS TTM
€0.50
Shares Outstanding
30.9M
EX-Date
--
P/E TM
68.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for GALAPAGOS NV (GLPG)

Related News

No related news articles were found.

galapagos nv (GLPG) Related Businessweek News

No Related Businessweek News Found

galapagos nv (GLPG) Details

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn’s disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.

417 Employees
Last Reported Date: 03/28/15
Founded in 1999

galapagos nv (GLPG) Top Compensated Officers

Co-Founder, Chief Executive Officer, Managing...
Total Annual Compensation: €696.5K
Compensation as of Fiscal Year 2014.

galapagos nv (GLPG) Key Developments

Galapagos NV - Special Call

To discuss the results of DARWIN 2 trial

Galapagos NV - Special Call

Galapagos NV - Special Call

Galapagos Seeks Acquisitions

Galapagos NV (ENXTBR:000381835) has filed a Follow-on Equity Offering, Galapagos NV use a portion of the net proceeds to in-license, acquire or invest in complementary technologies, products or assets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLPG:NA €34.10 EUR -2.95

GLPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLPG.
View Industry Companies
 

Industry Analysis

GLPG

Industry Average

Valuation GLPG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.0x
Price/Cash Flow 31.8x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALAPAGOS NV, please visit www.glpg.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.